| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
We investigated the efficacy of combination therapy using oncolytic adenovirus; OBP-401 which could replicate only within the tumor cells selectively and express green fluorescent protein (GFP) and chemotherapeutic agent, paclitaxel (PTX). OBP-401 synergistically suppressed the viability of two kinds of human SGC cells in combination with PTX in vitro. And PTX enhanced the efficacy of OBP-401 replication, resulted in synergistic effect. Peritoneal metastatic cells were visualized as GFP-positive cells selectively by the intra-peritoneal (i.p.) administration of OBP-401 in the orthotopic mouse model. The combination therapy with i.p. administration of OBP-401 and PTX could also significantly inhibited the tumor growth in vivo.
|
